Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tislelizumab + cisplatin + gemcitabine + trilaciclib + autologous bone marrow mononuclear cells
- Development stage
- Unknown
- Lead developer
- BeiGene
- Modality
- Stem Cell Therapies → Cell Therapies, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Intramyocardial
01
Overview
This entry represents a non-existent combination of two distinct therapeutic regimens: an oncology combination consisting of tislelizumab, cisplatin, gemcitabine, and trilaciclib, and a cell therapy for congestive heart failure developed by Harvest Technologies. The oncology component includes tislelizumab (a PD-1 inhibitor), cisplatin and gemcitabine (chemotherapeutic agents), and trilaciclib (a CDK4/6 inhibitor used to reduce chemotherapy-induced myelosuppression), typically investigated for advanced solid tumors such as small cell lung cancer. The heart failure component refers to the Harvest Technologies BMAC (Bone Marrow Aspirate Concentrate) system, which involves the autologous concentration of bone marrow nucleated cells for intramyocardial injection during coronary artery bypass grafting (CABG). This cell therapy aims to promote angiogenesis and myocardial repair in patients with ischemic congestive heart failure. There is no known clinical use or trial combining these five components.
- Other names
- Bone Marrow Aspirate ConcentrateBMAC Injection
02
Targets
CDK4 (Cyclin-dependent kinase 4)CDK6 (Cyclin-dependent kinase 6)DNAPDCD1 (Programmed cell death protein 1 receptor)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on tislelizumab + cisplatin + gemcitabine + trilaciclib + autologous bone marrow mononuclear cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tislelizumab + cisplatin + gemcitabine + trilaciclib + autologous bone marrow mononuclear cells.